Monday - May 12, 2025
INDIANAPOLIS / Jul 08, 2024 / Business Wire / Elevance Health released its annual Impact Report, highlighting its continued evolution from a traditional health insurance benefits company to a diversified healthcare services organization.
The report details significant achievements including the industry-leading Health Equity Accreditation Plus from the National Committee for Quality Assurance, support for Medicaid eligibility renewals, and growth of Carelon.
In Elevance Health’s ongoing efforts to make a meaningful and healthy impact on communities, its workforce, and the environment, the organization was again included in America’s top 50 most community-minded companies and JUST Capital’s JUST 100. Elevance Health is especially proud of its associates and their enthusiastic participation in connecting with members who are socially isolated or living with serious or terminal illness.
Emphasized throughout the Impact Report is Elevance Health’s progress on serving the unique needs of each health plan member, building capabilities to assess and address the key drivers of health, creating partnerships in communities to implement solutions to healthcare challenges, and using data-driven insights to simplify, connect and personalize healthcare.
Last Trade: | US$404.58 |
Daily Change: | -7.80 -1.89 |
Daily Volume: | 923,226 |
Market Cap: | US$93.830B |
April 22, 2025 January 23, 2025 October 17, 2024 July 17, 2024 April 18, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load